Auvelity is the first oral rapid-acting antidepressant for adults with major depressive disorder. In a six-week trial, Auvelity started working for some people as early as one week compared to a placebo. It was approved by the U.S. Food and Drug Administration in 2022.
Check our best Auvelity prices
Auvelity
Dextromethorphan hydrobromide and bupropion hydrochloride
Dopamine/norepinephrine reuptake inhibitor and NMDA antagonist
Extended-release tablet
By mouth
Auvelity is approved for adults with major depressive disorder.
Auvelity is a fast-acting antidepressant with improvement noted after one week versus other antidepressants, which can take four to eight weeks.
Auvelity is less likely to cause weight gain than other antidepressants.
It is expensive with no generic version available.
Extended-release tablet
45 mg dextromethorphan hydrobromide / 105 mg bupropion hydrochloride
Starting dose for depression in adults:
1 tablet once per day in the morning
After three days of treatment:
Increase to maximum recommended dosage of 1 tablet twice per day separated by at least 8 hours
Do not exceed two doses within the same day
Auvelity
45-105mg tablet extended release
Take Auvelity as instructed by your healthcare provider.
Do not take more than two tablets of Auvelity in 24 hours.
Do not take more than one dose of Auvelity at a time.
Do not change your dose or stop taking Auvelity without talking to your healthcare provider first.
Swallow Auvelity tablets whole.
Seek professional medical advice if you take too much Auvelity.
Do not take an extra dose to make up for a missed dose of Auvelity.
Wait and take your next dose at the regular time.
Do not take more than 1 dose of Auvelity at a time.
Do not take Auvelity if you:
Have a seizure disorder
Are currently or previously diagnosed with bulimia or anorexia nervosa
Abruptly discontinue alcohol, benzodiazepines, barbiturates, and antiepileptic drugs
Use MAOIs or have used MAOIs within 14 days of treatment with Auvelity
Are sensitive to bupropion, dextromethorphan, or other ingredients of Auvelity
Auvelity is not recommended for use in:
Pregnant women
Breastfeeding women
People with severe renal impairment
People with severe hepatic impairment
Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants.
Bupropion (an active ingredient in Auvelity) can cause seizures.
Elevated blood pressure and hypertension.
Increased risk of mania or hypomania, particularly in patients with bipolar disorder or those with risk factors for bipolar disorder.
Increased risk of psychosis and other neuropsychiatric reactions.
Auvelity may cause angle-closure glaucoma.
Dizziness was reported by 14% of people taking Auvelity in controlled studies (compared to 6% of patients on placebo).
Using Auvelity with SSRIs or tricyclic antidepressants may cause serotonin syndrome.
Based on animal studies, Auvelity may cause harm to the fetus when taken during pregnancy.
Auvelity should not be taken with:
Strong CYP2D6 inhibitors
Strong CYP2D6 inducers
CYP2D6 substrates
Digoxin
Drugs that lower seizure threshold
Dopaminergic drugs
Note: Auvelity can cause false-positive urine test results for amphetamines.
Auvelity can cause serious side effects. Please contact your doctor immediately or go the your local ER if you develop any of the following:
Suicidal thoughts and behaviors in adolescents and young adults
Seizure
Significantly elevated blood pressure
Activation of mania or hypomania
Psychosis and other neuropsychiatric reactions
Severe eye pain or blurred vision
Serotonin syndrome
Auvelity can also cause less serious side effects. Many of these side effects are mild and subside after the first week. If they persist, please inform your doctor. These side effects include:
Dizziness
Headache
Diarrhea
Drowsiness
Dry mouth
Sexual dysfunction
Excessive sweating
Nausea
Anxiety
Constipation
Decreased appetite
Insomnia
Joint pain
Fatigue
Paraesthesia (pins and needles sensation)
Auvelity prescribing information, FDA (2022)
About Auvelity, Axsome Therapeutics, Inc.
Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI), The Journal of Clinical Psychiatry (2022)
Peter Lourgos, MD, JD, was born and raised near Chicago. During his college years, he developed an interest in the intersection of law and medicine and subsequently enrolled in a dual degree medicine/law program at Southern Illinois University. He completed residency training in general and forensic psychiatry and is board-certified in both areas.
After completing his training, he worked as a criminal forensic psychiatrist for the Circuit Court of Cook County in Chicago, where he evaluated individuals charged with various crimes and reported his findings to the court. During this time, he served as a Clinical Associate Professor of Psychiatry, where he trained both medical students and resident physicians.
He has also served as a medical consultant to several large insurance providers.
Dr. Lourgos maintains an active clinical practice and sees patients for a variety of mental health concerns, including mood disorders, anxiety disorders, PTSD, and trauma. He has a passion for teaching others about mental health issues as it contributes to positive overall health and decreases the stigma often associated with mental health diagnoses.
...SingleCare es un servicio de descuentos para medicamentos recetados que ofrece cupones gratuitos para miles de medicamentos. Puedes usarlo aun si tienes seguro, Medicare, Medicaid o no, pero no se puede combinar con el seguro.
SingleCare ofrece transparencia al mostrar los precios de medicamentos para que puedas comparar descuentos en farmacias cerca de ti. Visita singlecare.com para encontrar descuentos en medicamentos, información útil sobre tu receta médica y recursos que te ayudan a tomar decisiones informadas sobre tu salud.
Los ahorros en recetas varían según la receta médica y la farmacia, y pueden alcanzar hasta un 80% de descuento sobre el precio en efectivo. Este es un plan de descuento de recetas médicas. NO es un seguro ni un plan de medicamentos de Medicare. El rango de descuentos para las recetas médicas que se brindan bajo este plan, dependerá de la receta y la farmacia donde se adquiera la receta y puede otorgarse hasta un 80% de descuento sobre el precio en efectivo. Usted es el único responsable de pagar sus recetas en la farmacia autorizada al momento que reciba el servicio, sin embargo, tendrá el derecho a un descuento por parte de la farmacia de acuerdo con el Programa de Tarifas de Descuento que negoció previamente. Towers Administrators LLC (que opera como “SingleCare Administrators”) es la organización autorizada del plan de descuento de recetas médicas ubicada en 4510 Cox Road, Suite 11, Glen Allen, VA 23060. SingleCare Services LLC (“SingleCare”) es la comercializadora del plan de descuento de prescripciones médicas que incluye su sitio web www.singlecare.com. Como información adicional se incluye una lista actualizada de farmacias participantes, así como también asistencia para cualquier problema relacionado con este plan de descuento de prescripciones médicas, comunícate de forma gratuita con el Servicio de Atención al Cliente al 844-234-3057, las 24 horas, los 7 días de la semana (excepto los días festivos). Al utilizar la aplicación o la tarjeta de descuento para recetas médicas de SingleCare acepta todos los Términos y Condiciones, para más información visita: https://www.singlecare.com/es/terminos-y-condiciones. Los nombres, logotipos, marcas y otras marcas comerciales de las farmacias son propiedad exclusiva de sus respectivos dueños.
Los artículos del blog no constituyen asesoramiento médico. Su propósito es brindar información general y no sustituyen el asesoramiento, diagnóstico ni tratamiento médico profesional. Si tiene alguna pregunta sobre una afección médica, consulte siempre a su médico u otro profesional de la salud cualificado. Si cree tener una emergencia médica, llame inmediatamente a su médico o al 911.
© 2026 SingleCare Administrators. Todos los derechos reservados
© 2026 SingleCare Administrators. Todos los derechos reservados